TWD 70.7
(-3.42%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | -926.77 Million TWD | -754.4% |
2022 | -108.47 Million TWD | 11.26% |
2021 | -122.23 Million TWD | 26.22% |
2020 | -165.66 Million TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q1 | -951.22 Million TWD | -2.64% |
2024 Q2 | -958.03 Million TWD | -0.71% |
2023 Q2 | -187.74 Million TWD | -44.12% |
2023 FY | -926.77 Million TWD | -754.4% |
2023 Q1 | -130.27 Million TWD | 0.0% |
2023 Q4 | -926.77 Million TWD | -10.25% |
2023 Q3 | -840.59 Million TWD | -347.74% |
2022 Q4 | - TWD | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Allied Biotech Corporation | 178.11 Million TWD | 620.331% |
GeneFerm Biotechnology Co., Ltd. | 31.92 Million TWD | 3002.894% |
Easywell Biomedicals, Inc. | 123.43 Million TWD | 850.811% |
TTY Biopharm Company Limited | -705.97 Million TWD | -31.276% |
Synmosa Biopharma Corporation | 1.52 Billion TWD | 160.92% |
Orient EuroPharma Co., Ltd. | 3.1 Billion TWD | 129.835% |
Center Laboratories, Inc. | 3.91 Billion TWD | 123.648% |
Tien Liang BioTech Co., Ltd. | -57.55 Million TWD | -1510.22% |
Orient Pharma Co., Ltd. | 633.6 Million TWD | 246.27% |
InnoPharmax Inc. | -17.85 Million TWD | -5089.708% |
Excelsior Biopharma Inc. | -212.51 Million TWD | -336.104% |
DV Biomed Co., Ltd. | 160.7 Million TWD | 676.713% |
Foresee Pharmaceuticals Co., Ltd. | -781.42 Million TWD | -18.601% |
Handa Pharmaceuticals, Inc. | -653.8 Million TWD | -41.751% |
UniPharma Co., Ltd. | -68.36 Million TWD | -1255.593% |
Anxo Pharmaceutical Co., Ltd. | 492.4 Million TWD | 288.214% |
Alar Pharmaceuticals Inc. | -738.05 Million TWD | -25.57% |
Winston Medical Supply Co., Ltd. | -191.81 Million TWD | -383.175% |
Mercury Biopharmaceutical Corporation | -1.94 Million TWD | -47549.254% |
Bioray Biotech Co., Ltd | -27.23 Million TWD | -3303.268% |
TSH Biopharm Corporation Limited | -568.74 Million TWD | -62.952% |